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Background
Immunization against chronic life threatening viral infec-
tions such as HIV remains an elusive goal. Data from clin-
ical and non-human primate studies suggest that the
generation of potent CD8 T cell responses as well as
broadly neutralizing antibodies will be needed for protec-
tive immunity against AIDS. Because of its well known
ability to stimulate such immune responses, we have
explored the potential of a replication-defective recom-
binant lymphocytic choriomeningitis virus (rLCMV) vec-
tor to elicit antigen-specific immunity to HIV-1.
Methods
We developed a packaging cell system to produce replica-
tion-defective vector and analyzed its ability to replicate in
vitro and in vivo. The immunogenicity of this vector was
evaluated by comparison of different prime boost vectors
encoding HIV-1 envelop (Env) using either DNA, recom-
binant adenovirus serotype 5 (rAd5) or alternative sero-
type rAd for priming followed by boosting with a rLCMV
vector in mice. T cell immunogenicity was assessed by
either analyzing tetramer positive cells or intracellular
cytokine staining after peptide stimulation and B cell
immunity by ELISA.
Results
The rLCMV vector was replication-defective, had no path-
ological consequences in mice injected intracerebrally
with vector, and efficiently infected dendritic cells. The
immune responses to rLCMV vaccination, alone or after
DNA or recombinant rAd5 priming were compared to
these vectors alone or to DNA/rAd5 prime boost immuni-
zations. This analysis revealed that rLCMV boosting of
DNA or rAd5 elicited Env-specific CD4 and CD8 T-cell
ICS responses of greater magnitude and persistence than
either vector alone or DNA/rAd5 immunization. Immu-
nogenicity in non-human primate studies is in progress
and will be discussed.
Conclusion
These results suggest that rLCMV represents a vaccine vec-
tor that targets dendritic cells and elicits potent and per-
sistent CD8 responses alone or in different prime boost
combinations. This vector merits further consideration for
clinical development of an AIDS vaccine.
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